Patient Stories
Meet Karen: a brave woman from the Latin community located in Chicago, who has treatment-resistant depression (TRD). Her internal struggles led to feelings of loneliness and isolation, affecting her daily life at work and at home. Karen had tried multiple antidepressants before her psychiatrist recommended a different approach: SPRAVATO® (esketamine), a nasal spray taken along with an oral antidepressant to treat TRD in adults. Learn more about Karen’s SPRAVATO® treatment story and her experience with treatment-resistant depression in this video.
Meet Ben: Ben is a real patient with treatment-resistant depression and has been compensated for his time by Janssen Pharmaceuticals, Inc. At the time of statement and/or production, Ben was treated with SPRAVATO® (esketamine) CIII nasal spray for treatment-resistant depression.
Meet Allison: Allison is a caregiver for her adult son with treatment-resistant depression (TRD). Caregivers are an important part of a patient’s journey with treatment-resistant depression. Learn more about Allison’s experience in this video.
Schedule a Consultation
Frequently Asked Questions
I’ve tried two or more oral antidepressants and I am still experiencing depression. Do you think I have treatment-resistant depression?
There is a study that suggests after the third oral antidepressant, remission rates dropped below 14%. If you’ve tried two or more oral antidepressants and are still experiencing depressive symptoms, you may have treatment-resistant depression and it may be time for something different.
Since my other oral antidepressants haven’t worked, what are the chances another oral antidepressant will work? Should I try something entirely different?
Treatment-resistant depression is defined as not responding to two or more antidepressants of adequate dose and duration. If your doctor has diagnosed you with treatment-resistant depression, you may benefit from treatment with a different kind of medication.
Can we talk about the SPRAVATO® clinical trials and discuss whether it may be a good choice for me?
It is helpful to understand the clinical trials for any medication you consider taking.
What can you tell me about the safety of SPRAVATO®?
It is important to understand the potential side effects of any medication you consider taking. To help ensure safety, SPRAVATO® is available only through a restricted distribution program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
What is a SPRAVATO® treatment center and how do I find one?
SPRAVATO® is only available at certified treatment centers and must be self-administered under the supervision of a healthcare provider.
Can you help me get financial support for SPRAVATO®?
Cost can sometimes impact a patient’s treatment journey; however, there may be affordability programs available to help eligible patients.
What is SPRAVATO® (esketamine) CIII nasal spray?
SPRAVATO® is a prescription medicine used:
- with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD)
- with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
